GILD · Nasdaq · CIK 0000882095
GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 16, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $29.4B and net income of $8.5B, according to its XBRL data on EDGAR. Its EDGAR record lists 84 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- GILEAD SCIENCES, INC.
- Ticker
- GILD
- SEC Central Index Key (CIK)
- 0000882095
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- FOSTER CITY, CA
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #71 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from GILEAD SCIENCES, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Net income | $6.2B | $4.6B | $5.7B | $480.0M | $8.5B |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Total assets | $68.0B | $63.2B | $62.1B | $59.0B | $59.0B |
| Cash and equivalents | $5.3B | $5.4B | $6.1B | $10.0B | $7.6B |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 24, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 6, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 4, 2026 | 8-K | Results of operations· period Aug 4, 2026 | Document · Index |
| Mar 20, 2026 | DEF 14A | DEFINITIVE PROXY STATEMENT· period Apr 30, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about GILEAD SCIENCES, INC., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026 | Document · Index |
| Oct 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026 | Document · Index |
| Oct 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Oct 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Oct 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026 | Document · Index |
| Sep 23, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 22, 2026 | Document · Index |
| Sep 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026 | Document · Index |
| Sep 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026 | Document · Index |
| Sep 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Sep 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Sep 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026 | Document · Index |
| Sep 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026 | Document · Index |
| Sep 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026 | Document · Index |
| Sep 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026 | Document · Index |
| Sep 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026 | Document · Index |
| Sep 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 1, 2026 | Document · Index |
| Aug 27, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 26, 2026 | Document · Index |
| Aug 26, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 26, 2026 | N-PX | N-PX· period Jun 30, 2026 | Document · Index |
| Aug 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 20, 2026 | Document · Index |
| Aug 20, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026 | Document · Index |
| Aug 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026 | Document · Index |
| Aug 17, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 17, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026 | Document · Index |
| Aug 7, 2026 | SCHEDULE 13D/A | Active beneficial ownership report (over 5%) | Document · Index |
| Aug 6, 2026 | S-3ASR | Simplified registration statement | Document · Index |
| Aug 6, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 3, 2026 | Document · Index |
| Aug 4, 2026 | 8-K | Results of operations· period Aug 4, 2026 | Document · Index |
| Aug 3, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 3, 2026 | 13F-HR | Institutional investment manager holdings report· period Jun 30, 2026 | Document · Index |
| Jul 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026 | Document · Index |
| Jul 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026 | Document · Index |
| Jul 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jul 15, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026 | Document · Index |
| Jun 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026 | Document · Index |
| Jun 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026 | Document · Index |
Insider filing activity
84 Form 4 filings appear in GILEAD SCIENCES, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- AMGN AMGEN INC
- MRNA Moderna, Inc.
- ARGX ARGENX SE
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- EXEL EXELIXIS, INC.
- NBIX NEUROCRINE BIOSCIENCES INC
All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000882095 and XBRL company facts. GILEAD SCIENCES, INC. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement